EP4426832A1 — Precise genome editing using retrons
Assigned to University of California · Expires 2024-09-11 · 2y expired
What this patent protects
Described herein are compositions and methods that provide precise editing of cells, including mammalian cells and human cells. The compositions and methods utilize retrons as repair donors, retron reverse transcriptases to make those retron repair donors, retron-encoded guide RN…
USPTO Abstract
Described herein are compositions and methods that provide precise editing of cells, including mammalian cells and human cells. The compositions and methods utilize retrons as repair donors, retron reverse transcriptases to make those retron repair donors, retron-encoded guide RNAs, and CRISPR nucleases.
Drugs covered by this patent
- Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.